Mutations in the BRCA1 and BRCA2 genes are known risk factors and drivers of breast and ovarian cancers. So far, few studies have been focused on understanding the differences in transcriptome and functional landscapes associated with the disease (breast vs. ovarian cancers), gene (BRCA1 vs. BRCA2), and mutation type (germline vs. somatic). In this study, we were aimed at systemic evaluation of the association of BRCA1 and BRCA2 germline and somatic mutations with gene expression, disease clinical features, outcome, and treatment. We performed BRCA1/2 mutation centered RNA-seq data analysis of breast and ovarian cancers from the TCGA repository using transcriptome and phenotype 'portrayal' with multi-layer self-organizing maps and functiona...
It is estimated that 5-10% of breast cancers (BC) and 25% of ovarian cancers (OC) are caused by inhe...
International audiencePurposeThe molecular mechanism of breast and/or ovarian cancer susceptibility ...
Previously, small studies have found that BRCA1 and BRCA2 breast tumors differ in their pathology. A...
BACKGROUND: Germline mutations in BRCA1 and BRCA2 are responsible for 5%-10% of epithelial ovarian c...
Background: Germline BRCA1/2 mutations are identified in 13-15% of ovarian cancers, while an additio...
This is the submission accompanying raw result files for multiple-layer SOM (ml-SOM) analysis for th...
Mutations in BRCA1 and BRCA2 cause deficiencies in homologous recombination repair (HR), resulting i...
Patients with inherited germline mutations in BRCA1/2 carry a drastically increased risk of early-on...
BRCA1 and BRCA2 are the most frequently mutated genes in ovarian cancer (OC) crucial both for the id...
Ovarian cancer (OC) is the fifth most common type of cancer in women and the fourth most common caus...
BRCA1 and BRCA2 mutations confer increased risk for development of breast cancer, but a number of ad...
PurposeHallmarks of germline BRCA1/2-associated ovarian carcinomas include chemosensitivity and impr...
No longer is histology solely predictive of cancer treatment and outcome. There is an increasing inf...
BACKGROUND: Poly (ADP-ribose) polymerase inhibitors targeting BRCA1/2 mutations are available for ...
BACKGROUND: A mutation found in the BRCA1 or BRCA2 gene of a breast tumor could be either germline o...
It is estimated that 5-10% of breast cancers (BC) and 25% of ovarian cancers (OC) are caused by inhe...
International audiencePurposeThe molecular mechanism of breast and/or ovarian cancer susceptibility ...
Previously, small studies have found that BRCA1 and BRCA2 breast tumors differ in their pathology. A...
BACKGROUND: Germline mutations in BRCA1 and BRCA2 are responsible for 5%-10% of epithelial ovarian c...
Background: Germline BRCA1/2 mutations are identified in 13-15% of ovarian cancers, while an additio...
This is the submission accompanying raw result files for multiple-layer SOM (ml-SOM) analysis for th...
Mutations in BRCA1 and BRCA2 cause deficiencies in homologous recombination repair (HR), resulting i...
Patients with inherited germline mutations in BRCA1/2 carry a drastically increased risk of early-on...
BRCA1 and BRCA2 are the most frequently mutated genes in ovarian cancer (OC) crucial both for the id...
Ovarian cancer (OC) is the fifth most common type of cancer in women and the fourth most common caus...
BRCA1 and BRCA2 mutations confer increased risk for development of breast cancer, but a number of ad...
PurposeHallmarks of germline BRCA1/2-associated ovarian carcinomas include chemosensitivity and impr...
No longer is histology solely predictive of cancer treatment and outcome. There is an increasing inf...
BACKGROUND: Poly (ADP-ribose) polymerase inhibitors targeting BRCA1/2 mutations are available for ...
BACKGROUND: A mutation found in the BRCA1 or BRCA2 gene of a breast tumor could be either germline o...
It is estimated that 5-10% of breast cancers (BC) and 25% of ovarian cancers (OC) are caused by inhe...
International audiencePurposeThe molecular mechanism of breast and/or ovarian cancer susceptibility ...
Previously, small studies have found that BRCA1 and BRCA2 breast tumors differ in their pathology. A...